Optiray 300 mg I/ml (12,72 g/20 ml) sol. inj. i.artér. flac. 벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

optiray 300 mg i/ml (12,72 g/20 ml) sol. inj. i.artér. flac.

guerbet - ioversol 12,72 g/20 ml - solution injectable - 300 mg i/ml - ioversol 12720 mg - ioversol

Optiray 350 mg I/ml (148,4 g/200 ml) sol. inj. i.artér. flac. 벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

optiray 350 mg i/ml (148,4 g/200 ml) sol. inj. i.artér. flac.

guerbet - ioversol 14,84 g/20 ml - solution injectable - 350 mg i/ml - ioversol 148400 mg - ioversol

Optiray 300 mg I/ml (63,6 g/100 ml) sol. inj. i.artér. flac. 벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

optiray 300 mg i/ml (63,6 g/100 ml) sol. inj. i.artér. flac.

guerbet - ioversol 12,72 g/20 ml - solution injectable - 300 mg i/ml - ioversol 63600 mg - ioversol

Optiray 300 mg I/ml (127,2 g/200 ml) sol. inj. i.artér. flac. 벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

optiray 300 mg i/ml (127,2 g/200 ml) sol. inj. i.artér. flac.

guerbet - ioversol 12,72 g/20 ml - solution injectable - 300 mg i/ml - ioversol 127200 mg - ioversol

Optiray 300 mg I/ml (38,16 g/60 ml) sol. inj. i.artér. flac. 벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

optiray 300 mg i/ml (38,16 g/60 ml) sol. inj. i.artér. flac.

guerbet - ioversol 12,72 g/20 ml - solution injectable - 300 mg i/ml - ioversol 38160 mg - ioversol

Optiray 350 mg I/ml (37,1 g/50 ml) sol. inj. i.artér. flac. 벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

optiray 350 mg i/ml (37,1 g/50 ml) sol. inj. i.artér. flac.

guerbet - ioversol 14,84 g/20 ml - solution injectable - 350 mg i/ml - ioversol 37100 mg - ioversol

Optiray 320 mg/ml sol. inj. i.artér. flac. 벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

optiray 320 mg/ml sol. inj. i.artér. flac.

guerbet - ioversol 13,56 g/20 ml - solution injectable - 320 mg/ml - ioversol 33900 mg - ioversol

Comirnaty 유럽 연합 - 프랑스어 - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Optiray 240 mg I/ml (25,45 g/50 ml) - 240 mg I/ml (50,9 g/100 ml) - 240 mg I/ml (101,8 g/200 ml) sol. inj. i.artér. flac. 벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

optiray 240 mg i/ml (25,45 g/50 ml) - 240 mg i/ml (50,9 g/100 ml) - 240 mg i/ml (101,8 g/200 ml) sol. inj. i.artér. flac.

guerbet - ioversol 7,635 g/15 ml - solution injectable - ioversol

Optiray 240 mg I/ml (25,45 g/50 ml) - 240 mg I/ml (50,9 g/100 ml) - 240 mg I/ml (101,8 g/200 ml) sol. inj. i.artér. flac. 벨기에 - 프랑스어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

optiray 240 mg i/ml (25,45 g/50 ml) - 240 mg i/ml (50,9 g/100 ml) - 240 mg i/ml (101,8 g/200 ml) sol. inj. i.artér. flac.

guerbet - ioversol 7,635 g/15 ml - solution injectable - ioversol